| Similar Articles |
|---|
 |
Bio-IT World
March 8, 2005
Salvatore Salamone |
Nano Poised for Liftoff First 'nano' technologies yield fruit in the biomedical lab and clinic with the promise of more to come.   |
Chemistry World
June 22, 2011
Sarah Houlton |
US Approves Cancer Drugs Twice as Fast as Europe Cancer drugs are, on average, approved nearly twice as fast in the US than they are in Europe. |
Chemistry World
July 10, 2012 |
Interview: EMA head Guido Rasi His five-year appointment comes during a period of dramatic change for the pharma industry, which is struggling with patent expirations for many of its biggest selling drugs and a paucity of new drugs coming through the pipeline to take their place. |
Chemistry World
January 3, 2013
Sarah Houlton |
2012 pharma industry roundup It may have been a relatively quiet year in terms of mergers and acquisitions, but the pharma industry nonetheless made plenty of headlines in 2012. |
Pharmaceutical Executive
October 1, 2011 |
The Essential--and Effective--Bureaucrat Fernand Sauer, First Director General, European Medicines Agency, has witnessed the progressive sterilization of innovative research due to a trend toward ever-larger industry concentration. |
Chemistry World
October 6, 2010
Hayley Birch |
US roadmap for nano development Nanotechnology is one of the largest and most competitive research fields globally, with the market for nanotechnology-based products exceeding $250 billion. |
Pharmaceutical Executive
November 1, 2013
Jill Wechsler |
Transparency Troubles for Pharma High prices, murky financial relations, and a reluctance to disclose clinical data undermine public trust in industry and the research enterprise. |
Pharmaceutical Executive
January 1, 2007
Glass & Poli |
Forecast 2007: Connecting the Dots How do execs rank the issues facing the pharmaceutical industry? And what are the links they see between them? A new study reveals the industry's mental map of today's challenges. |
Fast Company
May 2014
Adam Bluestein |
How IBM Is Using Nanotechnology To Tackle MRSA And HIV IBM's unusual nanomedicine program is tackling a range of ambitious projects: creating better antimicrobial and antifungal agents, new methods of drug delivery, and novel ways of combating such diseases as HIV/AIDS and tuberculosis. |
Pharmaceutical Executive
February 1, 2014 |
Will Europe's Regulatory Watchdog Come Of Age In 2014? The author looks at the growing pains of the European Medicine Agency as it faces key policy challenges of 2014. |
IEEE Spectrum
September 2007
Karn & Matthews |
Nano Particles Without Macroproblems Quick and dirty advice for keeping nanotech clean. |
Chemistry World
March 1, 2010
Rebecca Trager |
US launches new regulatory science program Two major US government agencies have partnered to create a new regulatory science program to ensure better integration between cutting edge science and regulatory processes in assessing new medical products or compounds flowing from biomedical research. |
Chemistry World
September 30, 2014 |
Transparency measures forced on pharma Previous misdemeanors are compelling the pharmaceutical industry to be more open with financial information and clinical data. |
Pharmaceutical Executive
November 1, 2014 |
EMA -- a Pioneer Permanently At Bay Agency's plan for reporting clinical trial data has sparked strong reactions from health campaigners, industry, and patients. |
